InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Gene Therapy For Retinal Diseases Market”-, By Indication (Choroideremia (CHM), Leber Congenital Amaurosis, Leber’s Hereditary Optic Neuropathy, X-Linked Retinitis Pigmentosa, and Other Indications), Cosmetics Industry, Academic & Research Institutes, Other End Users), and Global Forecasts, 2025-2034 And Segment Revenue and Forecast To 2031.”
The Gene Therapy For Retinal Diseases Market is expected to grow at an 8.0 % CAGR during the forecast period for 2023-2031.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1157
Gene therapy for retinal diseases offers a groundbreaking approach to treating inherited retinal disorders (IRDs) by directly targeting their underlying genetic causes. This innovative treatment strategy focuses on delivering functional gene copies, correcting mutations through gene editing, or silencing defective genes using advanced technologies like AAV vectors and CRISPR-Cas9 systems. These therapies specifically target key retinal cells, including photoreceptors & retinal pigment epithelium (RPE) cells, with the goal of preventing or restoring vision in conditions such as retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease, and choroideremia (CHM). The retina’s unique characteristics including its immune-privileged status and accessibility for monitoring make it especially suitable for gene-based interventions.
List of Prominent Players in the Gene Therapy For Retinal Diseases Market:
- Applied Genetic Technologies Corporation
- Adverum Biotechnologies
- ProQR Therapeutics
- MeiraGTx Limited.
- Oxford BioMedica
- Horama S.A.
- Gensight Biologics
- Regenxbio Inc.
- Spark Therapeutics, Inc.
- Genzyme (Sanofi)
- Novartis Pharmaceuticals
- Nightstar Therapeutics (Biogen)
- Hemera Biosciences
- ViGeneron GmbH
- Allergan
- Eyevensys
- Clearside Biomedical
- IVERIC bio, Inc.
- Other Prominent Players
Market Dynamics:
Market Drivers
The rising diagnosis rates of inherited retinal diseases (IRDs) like retinitis pigmentosa, Leber congenital amaurosis, and Stargardt disease are fueling demand for gene therapies. Increased availability of genetic testing and greater disease awareness are helping identify more patients who could benefit from these treatments.
Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1157
Market Challenges
Despite their potential, retinal gene therapies face significant barriers. The extremely high costs of these treatments put them out of reach for many patients, particularly where insurance coverage is limited. Treatment availability is also concentrated in certain regions, leaving patients in low and middle income countries with few options.
Regional Trends
North America currently dominates the retinal gene therapy market, supported by strong healthcare infrastructure, substantial R&D investment, and favourable regulatory policies. The region benefits from widespread genetic testing capabilities and insurance coverage for approved therapies like Luxturna. Meanwhile, the Asia Pacific region is emerging as the fastest-growing market, driven by increasing investments in genetic medicine and growing awareness of IRDs across major economies.
Recent Developments:
- In October 2023, Spark Therapeutics and SpliceBio declared a partnership and licensing deal whereby SpliceBio will employ its unique protein splicing platform to create a gene therapy for the treatment of an inherited retinal condition. The illness target’s specifics were not revealed. The deal calls for both businesses to work together on a research project using SpliceBio’s technological platform.
Curious about this latest version of the report? @
https://www.insightaceanalytic.com/customization/1157
Segmentation of Gene Therapy For Retinal Diseases Market.
Global Gene Therapy For Retinal Diseases Market – By Indication
- Choroideremia (CHM)
- Leber congenital amaurosis
- Leber’s hereditary optic neuropathy
- X-linked retinitis pigmentosa
- Other Indication
Global Gene Therapy For Retinal Diseases Market – By Region
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Get More Information : @
https://www.insightaceanalytic.com/report/global-gene-therapy-for-retinal-diseases-market-/1157
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
